TITLE

Potentials of Plasma NGAL and MIC-1 as Biomarker(s) in the Diagnosis of Lethal Pancreatic Cancer

AUTHOR(S)
Kaur, Sukhwinder; Chakraborty, Subhankar; Baine, Michael J.; Mallya, Kavita; Smith, Lynette M.; Sasson, Aaron; Brand, Randall; Guha, Sushovan; Jain, Maneesh; Wittel, Uwe; Singh, Shailender K.; Batra, Surinder K.
PUB. DATE
February 2013
SOURCE
PLoS ONE;Feb2013, Vol. 8 Issue 2, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Pancreatic cancer (PC) is lethal malignancy with very high mortality rate. Absence of sensitive and specific marker(s) is one of the major factors for poor prognosis of PC patients. In pilot studies using small set of patients, secreted acute phase proteins neutrophil gelatinase associated lipocalin (NGAL) and TGF-β family member macrophage inhibitory cytokine-1 (MIC-1) are proposed as most potential biomarkers specifically elevated in the blood of PC patients. However, their performance as diagnostic markers for PC, particularly in pre-treatment patients, remains unknown. In order to evaluate the diagnostic efficacy of NGAL and MIC-1, their levels were measured in plasma samples from patients with pre-treatment PC patients (n = 91) and compared it with those in healthy control (HC) individuals (n = 24) and patients with chronic pancreatitis (CP, n = 23). The diagnostic performance of these two proteins was further compared with that of CA19-9, a tumor marker commonly used to follow PC progression. The levels of all three biomarkers were significantly higher in PC compared to HCs. The mean (± standard deviation, SD) plasma NGAL, CA19-9 and MIC-1 levels in PC patients was 111.1 ng/mL (2.2), 219.2 U/mL (7.8) and 4.5 ng/mL (4.1), respectively. In comparing resectable PC to healthy patients, all three biomarkers were found to have comparable sensitivities (between 64%-81%) but CA19-9 and NGAL had a higher specificity (92% and 88%, respectively). For distinguishing resectable PC from CP patients, CA19-9 and MIC-1 were most specific (74% and 78% respectively). CA19-9 at an optimal cut-off of 54.1 U/ml is highly specific in differentiating resectable (stage 1/2) pancreatic cancer patients from controls in comparison to its clinical cut-off (37.1 U/ml). Notably, the addition of MIC-1 to CA19-9 significantly improved the ability to distinguish resectable PC cases from CP (p = 0.029). Overall, MIC-1 in combination with CA19-9 improved the diagnostic accuracy of differentiating PC from CP and HCs.
ACCESSION #
87623623

 

Related Articles

  • Plasma microRNA profiles: identification of miR-744 as a novel diagnostic and prognostic biomarker in pancreatic cancer. Miyamae, Mahito; Komatsu, Shuhei; Ichikawa, Daisuke; Kawaguchi, Tsutomu; Hirajima, Shoji; Okajima, Wataru; Ohashi, Takuma; Imamura, Taisuke; Konishi, Hirotaka; Shiozaki, Atsushi; Morimura, Ryo; Ikoma, Hisashi; Ochiai, Toshiya; Okamoto, Kazuma; Taniguchi, Hiroki; Otsuji, Eigo // British Journal of Cancer;11/17/2015, Vol. 113 Issue 10, p1467 

    Background: This study aims to explore novel microRNAs in plasma for screening cancer and predicting clinical outcomes in pancreatic cancer (PCa) patients using a microRNA array-based approach.Methods: We used the Toray 3D-Gene microRNA array-based approach to compare...

  • Fractalkine and TGF-β1 levels reflect the severity of chronic pancreatitis in humans. Yasuda, Mikihiko; Ito, Tetsuhide; Oono, Takamasa; Kawabe, Ken; Kaku, Toyoma; Igarashi, Hisato; Nakamura, Taichi; Takayanagi, Ryoichi // World Journal of Gastroenterology;11/14/2008, Vol. 14 Issue 42, p6488 

    AIM: To clarify whether serum chemokine and cytokine levels can become useful biological and functional markers to assess the severity of chronic pancreatitis (CP). This study aimed at clarifying whether serum chemokine and cytokine levels can become useful biological and functional markers to...

  • Smad3 and Smad3 Phosphoisoforms Are Prognostic Markers of Gastric Carcinoma. Kim, Seok-Hyung; Kim, Kyung-Hee; Ahn, Soomin; Hyeon, Jiyeon; Park, Cheol-Keun // Digestive Diseases & Sciences;Apr2013, Vol. 58 Issue 4, p989 

    Background: The transforming growth factor-β/Smads signaling pathway plays an important role in tumorigenesis and progression in cancer, and may closely be related to the biological behaviors of some malignant tumors, such as gastric carcinoma. In this study, we investigated the roles of...

  • Biomarkers of TGF-β Signaling Pathway and Prognosis of Pancreatic Cancer. Javle, Milind; Li, Yanan; Tan, Dongfeng; Dong, Xiaoqun; Chang, Ping; Kar, Siddhartha; Li, Donghui // PLoS ONE;Jan2014, Vol. 9 Issue 1, p1 

    Background: Transforming growth factor (TGF)-β signaling pathway, may act both as a tumor suppressor and as a tumor promoter in pancreatic cancer, depending on tumor stage and cellular context. TGF-β pathway has been under intensive investigation as a potential therapeutic target in the...

  • Proteins in Blood Reveal Pancreatic Tumors. Schmidt, Charlie // JNCI: Journal of the National Cancer Institute;Jul2014, Vol. 106 Issue 7, p1 

    The article reports on a study which found that combining carbohydrate antigen 19-9 (CA19-9), a blood marker for pancreatic cancer, with three other proteins improves its screening resolution. The combined protein panel correctly identified healthy control subjects 94% of the time. The ability...

  • Diagnostic and Prognostic Impact of Circulating YKL-40, IL-6, and CA 19.9 in Patients with Pancreatic Cancer. Schultz, Nicolai A.; Christensen, Ib J.; Werner, Jens; Giese, Nathalia; Jensen, Benny V.; Larsen, Ole; Bjerregaard, Jon K.; Pfeiffer, Per; Calatayud, Dan; Nielsen, Svend E.; Yilmaz, Mette K.; Holländer, Niels H.; Wøjdemann, Morten; Bojesen, Stig E.; Nielsen, Kaspar R.; Johansen, Julia S. // PLoS ONE;Jun2013, Vol. 8 Issue 6, p1 

    Purpose: We tested the hypothesis that high plasma YKL-40 and IL-6 associate with pancreatic cancer and short overall survival. Patients and Methods: In all, 559 patients with pancreatic cancer from prospective biomarker studies from Denmark (n = 448) and Germany...

  • The additional value of TGFβ1 and IL-7 to predict the course of prostate cancer progression. Schroten, Caroline; Dits, Natasja; Steyerberg, Ewout; Kranse, Ries; Leenders, Arno; Bangma, Chris; Kraaij, Robert // Cancer Immunology, Immunotherapy;Jun2012, Vol. 61 Issue 6, p905 

    Background: Given the fact that prostate cancer incidence will increase in the coming years, new prognostic biomarkers are needed with regard to the biological aggressiveness of the prostate cancer diagnosed. Since cytokines have been associated with the biology of cancer and its prognosis, we...

  • Age-dependent decrease in serum transforming growth factor (TGF)-beta 1 in healthy Japanese individuals; population study of serum TGF-beta 1 level in Japanese. Okamoto, Yoshihiro; Gotoh, Yoshimitsu; Uemura, Osamu; Tanaka, Soichi; Ando, Tsunesaburo; Nishida, Mikio // Disease Markers;2005, Vol. 21 Issue 2, p71 

    Transforming growth factor-beta1 (TGF-β1), a multi-functional cytokine, is involved in regulating a variety of cellular activities and the serum/plasma TGF-β1 level is altered with various diseases. However, most published reports have described adult patients, and so we investigated the...

  • TGF-Beta Blockade Increases Renal Inflammation Caused by the C-Terminal Module of the CCN2. Rodrigues-Díez, Raquel; Rayego-Mateos, Sandra; Orejudo, Macarena; Aroeira, Luiz Stark; Selgas, Rafael; Ortiz, Alberto; Egido, Jesús; Ruiz-Ortega, Marta // Mediators of Inflammation;5/5/2015, Vol. 2015, p1 

    The CCN family member 2 (CCN2, also known as connective tissue growth factor) may behave as a risk biomarker and a potential therapeutic target for renal disease. CCN2 participates in the regulation of inflammation and fibrosis. TGF-β is considered the main fibrogenic cytokine; however, in...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics